271 related articles for article (PubMed ID: 9440732)
1. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
3. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
Elledge RM; Green S; Howes L; Clark GM; Berardo M; Allred DC; Pugh R; Ciocca D; Ravdin P; O'Sullivan J; Rivkin S; Martino S; Osborne CK
J Clin Oncol; 1997 May; 15(5):1916-22. PubMed ID: 9164202
[TBL] [Abstract][Full Text] [Related]
4. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
5. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
6. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
[TBL] [Abstract][Full Text] [Related]
9. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
[TBL] [Abstract][Full Text] [Related]
11. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
[TBL] [Abstract][Full Text] [Related]
12. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.
Knoop AS; Bentzen SM; Nielsen MM; Rasmussen BB; Rose C
J Clin Oncol; 2001 Jul; 19(14):3376-84. PubMed ID: 11454885
[TBL] [Abstract][Full Text] [Related]
13. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.
van der Flier S; Brinkman A; Look MP; Kok EM; Meijer-van Gelder ME; Klijn JG; Dorssers LC; Foekens JA
J Natl Cancer Inst; 2000 Jan; 92(2):120-7. PubMed ID: 10639513
[TBL] [Abstract][Full Text] [Related]
14. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
Kai K; Nishimura R; Arima N; Miyayama H; Iwase H
Int J Clin Oncol; 2006 Dec; 11(6):426-33. PubMed ID: 17180510
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
[TBL] [Abstract][Full Text] [Related]
19. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
20. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]